This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Goodkin, D. E Search for Related Content PubMed Articles by Goodkin, D. E Social Bookmarking                         What's this?

MS clinical trial design for the future

UCSF/MT Zion Multiple Sclerosis Center, San Francisco, California, USA

The Clinical Outcomes Task Force has been challenged to develop new easily administered composite outcomes that are more sensitive, highly reliable, properly validated, and measure more effectively the broad spectrum of independent dimensions of MS. The Task Force on Use of MRI in MS Clinical Trials has already provided important position statements and recommendations for the use of magnetic imaging technologies in MS clinical trials. It appears mat T1WGd+activity and change in T2W lesion burden will be most useful as outcomes in patients who recently have experienced frequent relapses. It is anticipated that improved composite outcomes and more powerful statistical methods will facilitate improved predictive validity for MR imaging techniques. If we are successful in meeting these challenges, we should be able to conduct future definitive clinical trials more expeditiously and with fewer patients.

Key Words: multiple sclerosis • clinical trials

Multiple Sclerosis, Vol. 1, No. 6, 393-399 (1996)
DOI: 10.1177/135245859600100623


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?